Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories.
To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
----------------------------------------------
** BREAST CANCER News **
Metropolitan Chicago Breast Cancer Task Force Reports On Progress Toward Reducing The Black-White Disparity
http://www.medicalnewstoday.com/articles/126530.php
In what is gaining national recognition as a model for citywide collaboration to address racial health care disparities, <b>The Metropolitan Chicago Breast Cancer Task Force</b> delivered its first report to the community, one year after releasing a major report that outlined more than 30 recommendations for action.
Breast Cancer Mortality Gap Grows Between White, Black Women In Chicago, Report Says
http://www.medicalnewstoday.com/articles/126522.php
Chicago black women's mortality rate from breast cancer was 116% higher than that of white women in 2005, according to a new report from the <a href="http://www.sinai.org/urban/summit/index.asp" target="_new">Metropolitan Chicago Breast Cancer Task Force</a>, the <a href="http://www.
New York Times Columnist Discusses Best Practices For Breast Health
http://www.medicalnewstoday.com/articles/126496.php
<BR />The symptoms of breast cancer often are more prevalent than the disease itself, which can make decisions about further testing and treatment difficult, <A href="http://www.nytimes.com/2008/10/21/health/21brod.
----------------------------------------------
** CANCER / ONCOLOGY News **
Earlier-stage, Localized Renal Cell Carcinoma - Antigenics Submits Oncophage(R) Application For European Approval
http://www.medicalnewstoday.com/articles/126624.php
Antigenics Inc. (NASDAQ: AGEN) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) requesting approval for Oncophage® in earlier-stage, localized renal cell carcinoma (kidney cancer) under the conditional authorization provision.
ZymoGenetics Presents Interim IL-21 Phase 2 Results In Renal Cell Cancer
http://www.medicalnewstoday.com/articles/126623.php
ZymoGenetics, Inc. (NASDAQ: ZGEN) presented interim results today from a Phase 2 clinical trial evaluating Interleukin 21 (IL-21) in combination with Nexavar® (sorafenib) tablets in patients with metastatic renal cell cancer.
Exelixis Reports Positive Phase 1 Data For PI3K Inhibitor XL147 At EORTC-NCI-AACR Symposium
http://www.medicalnewstoday.com/articles/126622.php
Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from a phase 1 dose-escalation trial of XL147, a novel small molecule inhibitor of phosphoinositide-3 kinase (PI3K), which is implicated in tumor cell proliferation, survival, and resistance to chemotherapy and radiotherapy.
Aileron Advances First Stapled Peptide Drug Candidate That Targets Newly-Discovered BAX Activation Mechanism
http://www.medicalnewstoday.com/articles/126611.php
Aileron Therapeutics announced today that one of its proprietary Stapled Peptide compounds, referred to as "BIM-SAHB" in an article published today in <i>Nature</i>, was shown to uniquely target a new and fundamental activation mechanism of the programmed cell death or "apoptotic" pathway.
PharmaMar Presents New Data Of Zalypsis(R) And Irvalec(R) In Pediatric, Solid Tumours And Lymphoma
http://www.medicalnewstoday.com/articles/126608.php
PharmaMar, a biotechnology company of Zeltia Group, has presented new data on two antitumoral compounds of marine origin, Zalypsis® and Irvalec®, in Phase I trials in clinical development and in vitro studies and with animal models.
For Tumor Detection Bevacizumab Better Than Gold Standard Imaging
http://www.medicalnewstoday.com/articles/126606.php
Geneva, Switzerland: Scientists have developed a new imaging agent that can be used in scanning for tumours, and which gives a much clearer and more precise image than existing methods. The discovery has the potential to revolutionise pre-clinical cancer research and clinical diagnostic practice, and it makes use of compounds that have already been approved for treating patients: the anti-cancer drug bevacizumab (Avastin) and Copper-64, a radioactive copper nuclide, which is approved by the US Food and Drug Administration (FDA) for some clinical trials.
Validation Of Blood Brain Barrier Vector Technology Data Presented At EORTC-NCI-AACR Symposium
http://www.medicalnewstoday.com/articles/126602.php
AngioChem, Inc., a clinical-stage biotechnology company dedicated to creating and developing new drugs to treat brain diseases, has announced that its lead product, ANG1005, is safe and well tolerated in patients with brain cancer treated to date.
Neotropix(R) Announces Presentation Of Relevant Preclinical Results Of NTX-010 In Pediatric Oncology Models
http://www.medicalnewstoday.com/articles/126588.php
Neotropix(R), Inc., a clinical-stage development company focused on neuroendocrine cancer treatments, announced today exciting data from an extensive pediatric preclinical study performed by the National Cancer Institute (NCI) funded Pediatric Preclinical Testing Program on the use of NTX-010 (Seneca Valley Virus-001), a tumor-selective naturally-occurring oncolytic virus.
Scientists Unlock Secret Of Death Protein's Activation - May Lead To Drugs That Force Cancer Cells To Self-destruct
http://www.medicalnewstoday.com/articles/126570.php
Scientists at Dana-Farber Cancer Institute have identified a previously undetected trigger point on a naturally occurring "death protein" that helps the body get rid of unwanted or diseased cells.
Cohort Study Funded By Helmholtz
http://www.medicalnewstoday.com/articles/126549.php
The Helmholtz Association will invest around 20 million euros over the next five years to put together a large-scale, long-term cohort study. The goal of the study will be to illuminate the causes of common health problems like cardiovascular disease, cancer, diabetes and dementia, as well as to identify risk factors and effective methods of prevention.
Donor Cells For Immune Therapy For Patients With Leukaemia
http://www.medicalnewstoday.com/articles/126548.php
In the future, the bone marrow transfer to patients with leukaemia could be more secure. Experiments with mice have shown already that certain cells of the immune system (regulatory T cells or Tregs) can suppress the dangerous side effects resulting from the treatment.
Study Finds BRAF Mutations In Colorectal Cancer Cause Resistance To Anti-EGFR Therapy
http://www.medicalnewstoday.com/articles/126542.php
European researchers have found that metastatic colorectal cancer patients with a mutation in the BRAF gene do not respond to anti-EGFR therapy with cetuximab and panitumumab. The finding could help doctors better identify which patients are likely to benefit from such treatment, which is commonly used as last-effort therapy but only works in a fraction of patients.
Early Trial Of New Multi-Kinase Inhibitor Shows Impressive Activity In Medullary Thyroid Cancer
http://www.medicalnewstoday.com/articles/126541.php
Preliminary trials of a new multi-kinase inhibitor have indicated it has impressive tumour shrinkage activity in patients with a difficult to treat type of thyroid cancer. The results have put the drug's development on a fast track, prompting the accelerated initiation of a large phase III trial.
Cancer Patients' Response To Chemotherapy Improved By Eating Fruit And Vegetables
http://www.medicalnewstoday.com/articles/126531.php
The leading cause of death in all cancer patients continues to be the resistance of tumor cells to chemotherapy, a form of treatment in which chemicals are used to kill cells.Now a study by UC Riverside biochemists that focuses on cancer cells reports that ingesting apigenin - a naturally occurring dietary agent found in vegetables and fruit - improves cancer cells' response to chemotherapy.
Cancer Groups Collaborate For Initiative To Boost Number Of Minority Oncologists
http://www.medicalnewstoday.com/articles/126525.php
<a href="http://cms.komen.org/komen/index.htm" target="_new">Susan G. Komen for the Cure</a> and the <a href="http://www.asco.org/" target="_new">American Society of Clinical Oncology</a> have partnered to create the <a href="http://www.
----------------------------------------------
** CERVICAL CANCER / HPV VACCINE News **
No news for this category today.
----------------------------------------------
** COLORECTAL CANCER News **
Study Published In NEJM Shows K-ras Gene Mutation Status May Affect Response To ERBITUX(R) Treatment
http://www.medicalnewstoday.com/articles/126592.php
ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced the publication of study results showing that metastatic colorectal cancer (mCRC) patients with wild-type or "normal" K-ras tumors who were treated with ERBITUX® (cetuximab) plus best supportive care (BSC) had a statistically significant increase in overall survival and progression-free survival compared to those treated with BSC alone.
Response In Advanced Bowel Cancer Predicted By Gene Expression Pattern
http://www.medicalnewstoday.com/articles/126581.php
Geneva, Switzerland: Research by scientists in France has shown for the first time that identifying patterns of gene expression can be used to predict response to treatment in patients with advanced metastatic colorectal cancer.
Study Finds BRAF Mutations In Colorectal Cancer Cause Resistance To Anti-EGFR Therapy
http://www.medicalnewstoday.com/articles/126542.php
European researchers have found that metastatic colorectal cancer patients with a mutation in the BRAF gene do not respond to anti-EGFR therapy with cetuximab and panitumumab. The finding could help doctors better identify which patients are likely to benefit from such treatment, which is commonly used as last-effort therapy but only works in a fraction of patients.
Poniard Announces Positive Incremental Efficacy And Safety Data From Phase 2 Picoplatin Trial In Patients With Metastatic Colorectal Cancer
http://www.medicalnewstoday.com/articles/126456.php
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, announced positive incremental data from its randomized, controlled Phase 2 clinical trial of picoplatin in patients with metastatic colorectal cancer (CRC).
----------------------------------------------
** LUNG CANCER News **
New Light Shed On Lung Cancer By Large-Scale Genetic Study
http://www.medicalnewstoday.com/articles/126607.php
A multi-institution team, funded by the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH), have reported results of the largest effort to date to chart the genetic changes involved in the most common form of lung cancer, lung adenocarcinoma.
Unraveling The Genetic Picture Of Lung Cancer
http://www.medicalnewstoday.com/articles/126537.php
A study seeking possible cancer genes elucidated the mutations and the genetic pathways activated in the most common form of lung cancer - lung adenocarcinoma - and could lead to improved diagnosis and treatment, said the director of the Baylor College of Medicine Human Genome Sequencing Center that played a major role in the project led by the National Human Genome Research Institute.
Genome Study Finds 26 Lung Cancer Genes
http://www.medicalnewstoday.com/articles/126472.php
US scientists working on the largest study ever to map the genetic changes involved in lung adenocarcinoma have identified 26 genes that are frequently mutated in this most common form of lung cancer, further increasing opportunities for individualized diagnosis and treatment of the country's leading cause of cancer deaths.
Landmark Genomic Study Of Lung Cancer Published In Nature
http://www.medicalnewstoday.com/articles/126470.php
Scientists announced the results of the largest genomic study to date of lung adenocarcinoma, the most common form of lung cancer. Led by researchers from the Broad Institute of Harvard and MIT, Dana-Farber Cancer Institute, and other research institutions nationwide, the collaborative study unearthed a variety of genetic alterations in patient tumors and pinpointed 26 frequently altered genes more than doubling the number already linked to the disease.
Scientists Find New Genes Linked To Lung Cancer
http://www.medicalnewstoday.com/articles/126468.php
Working as part of a multi-institutional collaboration, scientists at Washington University School of Medicine in St. Louis have assembled the most complete catalog to date of the genetic changes underlying the most common form of lung cancer.
----------------------------------------------
** LYMPHOMA / LEUKEMIA News **
PharmaMar Presents New Data Of Zalypsis(R) And Irvalec(R) In Pediatric, Solid Tumours And Lymphoma
http://www.medicalnewstoday.com/articles/126608.php
PharmaMar, a biotechnology company of Zeltia Group, has presented new data on two antitumoral compounds of marine origin, Zalypsis® and Irvalec®, in Phase I trials in clinical development and in vitro studies and with animal models.
Potential Reversal Of Leukemia By Silencing A Protein
http://www.medicalnewstoday.com/articles/126596.php
Blocking the signals from a protein that activates cells in the immune system could help kill cells that cause a rare form of blood cancer, according to physicists and oncologists who combined computer modeling and molecular biology in their discovery.
Link Between Gene Variations And Cancer Survival Revealed By U Of MN Study
http://www.medicalnewstoday.com/articles/126552.php
Scientific research shows that certain genes can influence a person's likelihood to contract particular diseases, cancer for example. New research at the Masonic Cancer Center, University of Minnesota demonstrates that genetic markers may also show a person's likelihood to survive the disease.
Link Between Gene Variations And Cancer Survival Revealed By U Of MN Study
http://www.medicalnewstoday.com/articles/126551.php
Scientific research shows that certain genes can influence a person's likelihood to contract particular diseases, cancer for example. New research at the Masonic Cancer Center, University of Minnesota demonstrates that genetic markers may also show a person's likelihood to survive the disease.
Donor Cells For Immune Therapy For Patients With Leukaemia
http://www.medicalnewstoday.com/articles/126548.php
In the future, the bone marrow transfer to patients with leukaemia could be more secure. Experiments with mice have shown already that certain cells of the immune system (regulatory T cells or Tregs) can suppress the dangerous side effects resulting from the treatment.
Socioeconomic Status Plays Role In Whether Patients Receive Appropriate Treatment For Non-Hodgkin Lymphoma, Study Finds
http://www.medicalnewstoday.com/articles/126521.php
Socioeconomic factors such as income and education appear to affect whether people with non-Hodgkin lymphoma receive appropriate treatment, according to a study in the journal <cite>Cancer</cite>, <a href="http://www.
----------------------------------------------
** PROSTATE / PROSTATE CANCER News **
Nymox Nears Completion Of New One Year U.S. Study Of Benign Prostatic Hyperplasia Drug
http://www.medicalnewstoday.com/articles/126613.php
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the Company's latest multi-center U.S. study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH), is nearing completion.
Poniard Announces Positive Incremental Efficacy And Safety Data From Ongoing Phase 2 Picoplatin Trial In Hormone-Refractory Prostate Cancer
http://www.medicalnewstoday.com/articles/126455.php
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, announced positive incremental data from its ongoing Phase 2 clinical trial of picoplatin in combination with docetaxel and prednisone as first-line therapy for metastatic hormone-refractory prostate cancer (HRPC).
-------------------------------------------------------------
You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
No comments:
Post a Comment